banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Kim  Paraiso

Kim Paraiso

Kim Paraiso



Dr. Kim Paraiso successfully defended her dissertation on February 18, 2015 and is pictured here with her Committee. From l to r: Conor Lynch, Alvaro Monteiro, Kim, Eric Haura directly behind her, her external chair Elena Pasquale from the Sanford-Burnham Medical Research Institute in San Diego, Geoff Gibney and major professor Keiran Smalley. Dr. Paraiso has accepted a position in the lab of Dr. Thomas Graeber, UCLA

Dr. Paraiso's Publication Record while in the Program:

Paraiso KH, Thakur MD, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype. Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290. PMID:25542447

CDSmyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, Smalley KS, Wallis NG. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther. 2014 Dec;13(12):2793-804. doi: 10.1158/1535-7163.MCT-14-0452. Epub 2014 Oct 27.PMID:25349308-14-0293.

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. PMID: 25130256

Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Mol Cell Proteomics. 2014 Apr 23.PMID:24760959

Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer.Biochem Pharmacol. 2013 Jan 29. doi:pii: S0006-2952(13)00055-5. 10.1016/j.bcp.2013.01.018.PMID:23376122

Beck D, Niessner H, Smalley K.S.M., Flaherty K, Paraiso K. H.T., Busch C, Sinnberg T, Vasseur S, Iovanna J, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D and Meier F. Vemurafenib potently induces endoplasmic reticulum (ER) stress and ER stress-mediated apoptosis in BRAFV600E melanoma cells. Science Signaling. 2013 Jan 29; 6 (260).

Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak V, Koomen JM, Smalley KS. Inhibition of Wee1, AKT and CDK4 following treatment with the HSP90 inhibitor XL888 in NRAS mutant melanoma. Mol Cancer Ther. 2013 Mar 28 Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol. 2013 Apr 15;85(8):1033-41.

Collazo MM, Paraiso KH, Park MY, Hazen AL, Kerr WG. Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP. Eur J Immunol. 2012 Jul;42(7):1785-95.

John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS. GSK3ß Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation. J Invest Dermatol. 2012 Jul 19. doi: 10.1038/jid.2012.237.

Paraiso KHT and Smalley KSM. Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. Cancer Discov. 2012 May;2(5):390-2.

Paraiso KH, John J, Smalley KS. Skin Cancer and Melanoma, Biotargets of Cancer in Current Clinical Practice, M. Bologna Editor, Springer/Humana Press, New York, April 2012

Paraiso KH, Haarberg E, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John J, Sarnaik AA, Koomen J, Smalley KS. The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May 1;18(9):2502-14.

Kudchadkar R,Paraiso KH, Smalley KS. Targeting Mutant BRAF in Melanoma: Current Status and Future Development of Combination Therapy Strategies. Cancer J. 2012 Mar;18(2):124-31.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011 Apr 1;71(7):2750-60.

Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011 Aug 1;82(3):201-9. Epub 2011 May 25. Review.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714.PMID:20531415

Paraiso KH, Van Der Kooi K, Messina JL, Smalley KS. Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines. Methods Enzymol. 2010;484:549-67.